<DOC>
	<DOCNO>NCT02326584</DOCNO>
	<brief_summary>This study examine safety profile vadastuximab talirine ( SGN-CD33A ) ( monotherapy ) combination standard treatment . The main purpose study find best dose schedule SGN-CD33A give combination standard induction treatment , combination standard consolidation treatment , maintenance treatment . This determine observe dose-limiting toxicity ( side effect prevent increase dose ) SGN-CD33A . In addition , pharmacokinetic profile anti-leukemic activity study treatment assess .</brief_summary>
	<brief_title>A Safety Study SGN-CD33A Combination With Standard-of-care Patients With AML</brief_title>
	<detailed_description>The study conduct follow distinct part : Part A : Induction dose escalation - 7+3 combine SGN-CD33A ( Day 1 Day 4 dose ) Part B : Consolidation dose escalation - consolidation combine SGN-CD33A ; 4 cycle consolidation therapy administer SGN-CD33A ( Day 1 cycle ) . Part C : Maintenance - SGN-CD33A Monotherapy ; Up 24 patient 24 patient without prior allogeneic stem cell transplant treat SGN-CD33A . Both arm enroll simultaneously . SGN-CD33A administered Day 1 6-week cycle 8 cycle . Part D : Induction plus consolidation - induction/consolidation combine SGN-CD33A ; patient achieve CR/CRi ( without second induction ) receive 4 cycle consolidation therapy administer SGN-CD33A ( Day 1 cycle ) . Part E : Induction dose escalation - 7+3 combine SGN-CD33A ( Day 1 dosing )</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<criteria>All subtypes Acute Myeloid leukemia ( except acute promyelocytic leukemia ) Eastern Cooperative Oncology Group status 0 1 Adequate baseline renal hepatic function Central venous access Part specific requirement : eligible receive induction ; achieve CR/CRi standard induction eligible receive consolidation ; CR document blood count recovery maintenance Previous treatment MDS MPN dose escalation cohort Inadequate lung function Inadequate heart function</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Acute Myeloid Leukemia</keyword>
	<keyword>Antibody-Drug Conjugate</keyword>
	<keyword>CD33 Antigen</keyword>
	<keyword>Drug Therapy</keyword>
	<keyword>Acute Myelogenous Leukemia</keyword>
</DOC>